Estrogen increases expression of vascular alpha 2C adrenoceptor through the cAMP/Epac/JNK/AP-1 pathway and potentiates cold-induced vasoconstriction
| dc.contributor.author | Fardoun, Manal Muin | |
| dc.contributor.author | Issa, Khodr | |
| dc.contributor.author | Maaliki, Dina S. | |
| dc.contributor.author | Nasser, Suzanne A. | |
| dc.contributor.author | Baydoun, Elias Abdel Hasan | |
| dc.contributor.author | Eid, Ali H. | |
| dc.contributor.department | Department of Biology | |
| dc.contributor.department | Pharmacology and Toxicology | |
| dc.contributor.faculty | Faculty of Arts and Sciences (FAS) | |
| dc.contributor.faculty | Faculty of Medicine (FM) | |
| dc.contributor.institution | American University of Beirut | |
| dc.date.accessioned | 2025-01-24T11:20:55Z | |
| dc.date.available | 2025-01-24T11:20:55Z | |
| dc.date.issued | 2020 | |
| dc.description.abstract | Cutaneous cold-induced vasoconstriction is a normal physiological reaction mediated by alpha 2C-adrenergic receptors (α2C-ARs) expressed in vascular smooth muscle cells (VSMCs). When this reaction is exaggerated, Raynaud's phenomenon (RP) ensues. RP is more prevalent in females compared to age-matched men. We previously established that 17-β estradiol (estrogen) upregulates α2C-ARs in human VSMCs via a cAMP/Epac/Rap pathway. We also showed that cAMP acts through JNK to increase α2C-AR expression. However, whether estrogen employs JNK to regulate α2C-AR is not investigated. Knowing that the α2C-AR promoter harbors an activator protein-1 (AP-1) binding site that can be potentially activated by JNK, we hypothesized that estrogen regulates α2C-AR expression through an Epac/JNK/AP-1 pathway. Our results show that estrogen (10−10 M) activated JNK in human VSMCs extracted from cutaneous arterioles. Pretreatment with ESI09 (10 μM; an Epac inhibitor), abolished estrogen-induced JNK activation. In addition, pre-treatment with SP600125 (3 μM; a JNK specific inhibitor) abolished estrogen-induced expression of α2C-AR. Importantly, estrogen-induced activation of α2C-AR promoter was attenuated with SP600125. Moreover, transient transfection of VSMCs with an Epac dominant negative mutant (Epac-DN) abolished estrogen-induced activation of α2C-AR promoter. However, co-transfection of constitutively active JNK mutant overrode the inhibitory effect of Epac-DN on α2C-AR promoter. Moreover, estrogen caused a concentration-dependent increase in the activity of AP-1-driven reporter construct. Mutation of AP-1 site in the α2C-AR promoter abolished its activation by estrogen. This in vitro estrogen-increased α2C-AR expression was mirrored by an increase in the ex vivo functional responsiveness of arterioles. Indeed, estrogen potentiated α2C-AR-mediated cold-induced vasoconstriction, which was abolished by SP600125. Collectively, these results indicate that estrogen upregulates α2C-AR expression via an EPAC-mediated JNK/AP-1- dependent mechanism. These results provide an insight into the mechanism by which exaggerated cold-induced vasoconstriction occurs in estrogen-replete females and identify Epac and JNK as potential targets for the treatment of RP. © 2020 | |
| dc.identifier.doi | https://doi.org/10.1016/j.vph.2020.106690 | |
| dc.identifier.eid | 2-s2.0-85086744901 | |
| dc.identifier.pmid | 32407896 | |
| dc.identifier.uri | http://hdl.handle.net/10938/25166 | |
| dc.language.iso | en | |
| dc.publisher | Elsevier Inc. | |
| dc.relation.ispartof | Vascular Pharmacology | |
| dc.source | Scopus | |
| dc.subject | Ap-1 | |
| dc.subject | Estrogen | |
| dc.subject | Jnk | |
| dc.subject | Raynaud's phenomenon | |
| dc.subject | Vasoconstriction | |
| dc.subject | Α2c-adrenergic receptor | |
| dc.subject | Animals | |
| dc.subject | Arterioles | |
| dc.subject | Cells, cultured | |
| dc.subject | Cold temperature | |
| dc.subject | Cyclic amp | |
| dc.subject | Estradiol | |
| dc.subject | Guanine nucleotide exchange factors | |
| dc.subject | Humans | |
| dc.subject | Jnk mitogen-activated protein kinases | |
| dc.subject | Male | |
| dc.subject | Mice, inbred c57bl | |
| dc.subject | Muscle, smooth, vascular | |
| dc.subject | Myocytes, smooth muscle | |
| dc.subject | Raynaud disease | |
| dc.subject | Receptors, adrenergic, alpha-2 | |
| dc.subject | Signal transduction | |
| dc.subject | Tail | |
| dc.subject | Transcription factor ap-1 | |
| dc.subject | Up-regulation | |
| dc.subject | Ab 120657 | |
| dc.subject | Alpha 2c adrenergic receptor | |
| dc.subject | Anthra[1,9 cd]pyrazol 6(2h) one | |
| dc.subject | Binding protein | |
| dc.subject | Epac protein | |
| dc.subject | Esi 09 | |
| dc.subject | Protein inhibitor | |
| dc.subject | Stress activated protein kinase | |
| dc.subject | Transcription factor ap 1 | |
| dc.subject | Unclassified drug | |
| dc.subject | Adra2c protein, human | |
| dc.subject | Alpha 2 adrenergic receptor | |
| dc.subject | Guanine nucleotide exchange factor | |
| dc.subject | Rapgef3 protein, human | |
| dc.subject | Animal cell | |
| dc.subject | Animal experiment | |
| dc.subject | Animal tissue | |
| dc.subject | Arteriole | |
| dc.subject | Article | |
| dc.subject | Binding site | |
| dc.subject | Cold | |
| dc.subject | Controlled study | |
| dc.subject | Drug antagonism | |
| dc.subject | Drug mechanism | |
| dc.subject | Enzyme activation | |
| dc.subject | Ex vivo study | |
| dc.subject | Genetic transfection | |
| dc.subject | Human | |
| dc.subject | Human cell | |
| dc.subject | In vitro study | |
| dc.subject | Mouse | |
| dc.subject | Nonhuman | |
| dc.subject | Priority journal | |
| dc.subject | Promoter region | |
| dc.subject | Protein expression | |
| dc.subject | Protein function | |
| dc.subject | Protein transport | |
| dc.subject | Raynaud phenomenon | |
| dc.subject | Transient transfection | |
| dc.subject | Upregulation | |
| dc.subject | Vascular smooth muscle cell | |
| dc.subject | Animal | |
| dc.subject | C57bl mouse | |
| dc.subject | Cell culture | |
| dc.subject | Drug effect | |
| dc.subject | Enzymology | |
| dc.subject | Genetics | |
| dc.subject | Metabolism | |
| dc.subject | Pathophysiology | |
| dc.subject | Smooth muscle cell | |
| dc.subject | Vascular smooth muscle | |
| dc.subject | Vascularization | |
| dc.title | Estrogen increases expression of vascular alpha 2C adrenoceptor through the cAMP/Epac/JNK/AP-1 pathway and potentiates cold-induced vasoconstriction | |
| dc.type | Article |
Files
Original bundle
1 - 1 of 1